Hutchinson -Gilford progeria syndrome (HGPS) is caused by a mutant prelamin A, progerin, that terminates with a farnesylcysteine. HGPS knock-in mice (Lmna HG/1 ) develop severe progeria-like disease phenotypes. These phenotypes can be ameliorated with a protein farnesyltransferase inhibitor (FTI), suggesting that progerin's farnesyl lipid is important for disease pathogenesis and raising the possibility that FTIs could be useful for treating humans with HGPS. Subsequent studies showed that mice expressing non-farnesylated progerin (Lmna nHG/1 mice, in which progerin's carboxyl-terminal -CSIM motif was changed to -SSIM) also develop severe progeria, raising doubts about whether any treatment targeting protein prenylation would be particularly effective. We suspected that those doubts might be premature and hypothesized that the persistent disease in Lmna nHG/1 mice could be an unanticipated consequence of the cysteine-to-serine substitution that was used to eliminate farnesylation. To test this hypothesis, we generated a second knock-in allele yielding non-farnesylated progerin (Lmna csmHG ) in which the carboxyl-terminal -CSIM motif was changed to -CSM. We then compared disease phenotypes in mice harboring the Lmna nHG or Lmna csmHG allele. As expected, Lmna nHG/1 and Lmna nHG/nHG mice developed severe progeria-like disease phenotypes, including osteolytic lesions and rib fractures, osteoporosis, slow growth and reduced survival. In contrast, Lmna csmHG/1 and Lmna csmHG/csmHG mice exhibited no bone disease and displayed entirely normal body weights and survival. The frequencies of misshapen cell nuclei were lower in Lmna csmHG/1 and Lmna csmHG/csmHG fibroblasts. These studies show that the ability of non-farnesylated progerin to elicit disease depends on the carboxyl-terminal mutation used to eliminate protein prenylation.
INTRODUCTION
Hutchinson -Gilford progeria syndrome (HGPS), the classic progeroid syndrome of children, is caused by a mutant form of prelamin A, generally called progerin, that contains an internal 50-amino acid deletion within the carboxyl-terminal region of the protein. The deletion leaves progerin's carboxylterminal CaaX motif intact, so the protein undergoes the usual CaaX motif posttranslational modifications (farnesylation of the cysteine, release of the last three amino acids and methylation of the farnesylcysteine) (1 -7) . Recently, we created mice harboring an HGPS knock-in allele (Lmna HG ) and identified severe disease phenotypes resembling those in humans with HGPS (8, 9) . The disease phenotypes in Lmna HG/+ mice were ameliorated with a protein farnesyltransferase inhibitor (FTI), suggesting that the protein prenylation is important for disease pathogenesis (9 -11) . To further explore this issue, we created a knock-in allele encoding a non-farnesylated version of progerin (Lmna nHG , in which progerin's carboxyl-terminal -CSIM motif was changed to -SSIM) (12) . The single amino acid substitution abolishes protein prenylation and the two subsequent processing steps (release of the last three amino acids and carboxyl methylation). We anticipated that mice harboring that allele (Lmna nHG/+ ) would be free of disease, but to our surprise they developed all of the same disease phenotypes found in Lmna HG/+ mice and invariably succumbed to the disease (12) . The disease in Lmna nHG/+ mice tended to be milder than in Lmna HG/+ mice, but that was likely due to lower steady-state levels of progerin within tissues (12) . In any case, the persistence of severe disease in Lmna nHG/+ mice, where the progerin was non-prenylated, raised doubts about the primacy of the protein prenylation in disease pathogenesis.
The severe disease in mice harboring a Lmna nHG allele sounded mixed messages. On the one hand, the fact that the disease was somewhat milder in Lmna nHG/+ mice raised hopes that FTI therapy might ameliorate disease in humans with HGPS, perhaps by lowering levels of progerin in tissues. But on the other hand, the fact that non-farnesylated progerin was toxic and invariably caused the demise of Lmna nHG/+ mice sounded a pessimistic note, implying that 'anti-prenylation' drug therapy would never be particularly effective. However, the pessimistic view is subject to a caveat. The progerin produced by the Lmna nHG allele terminates with -SSIM, while non-prenylated progerin in FTItreated Lmna HG/+ mice would terminate with -CSIM. Although the amino acid substitution is subtle (amounting to the replacement of a single sulfur atom with an oxygen), its potential importance cannot be dismissed. Single amino acid substitutions in prelamin A and lamin C cause a potpourri of human diseases (13) (14) (15) , even progeroid syndromes (1, 16, 17) . Thus, it is conceivable that the toxicity of SSIM progerin could be due to the cysteine-to-serine substitution. Following the same reasoning, it is conceivable that the non-prenylated CSIM progerin that accumulates in FTI-treated Lmna HG/+ mice might be non-toxic and incapable of promoting disease.
We are not aware of any experimental strategy that would allow one to directly test the toxicity of non-farnesylated CSIM progerin, simply because there is no way to eliminate protein prenylation in vivo without altering the last four amino acids of the protein (the residues that trigger protein prenylation). But fully understanding the properties of nonfarnesylated progerin is important. Accordingly, we generated a second non-farnesylated progerin allele, one that terminates with -CSM rather than -SSIM. CSM progerin lacks the isoleucine within progerin's CaaX motif and cannot be prenylated, but it retains a carboxyl-terminal cysteine (like the CSIM progerin that accumulates during FTI treatment) (9) . In the current study, we compared, side-by-side, the phenotypes of mice harboring the Lmna csmHG or Lmna nHG allele.
RESULTS
We used gene targeting to create a mutant Lmna allele, Lmna csmHG , that yields exclusively non-farnesylated progerin (Fig. 1A) . The Lmna csmHG allele is designed to produce nonfarnesylated progerin and is identical to the Lmna HG allele produced earlier (8) except that the isoleucine within the CaaX motif was deleted. Targeted embryonic stem (ES) cells, which were identified by Southern blotting (Fig. 1B) , were used to create the Lmna csmHG mouse model. Western blots revealed that Lmna csmHG/csmHG mice produced progerin (and no lamin A or lamin C); Lmna csmHG/+ mice produced progerin from the mutant allele along with lamins A and C from the wild-type allele (Fig. 1C) .
To verify that the progerin produced by Lmna csmHG/+ mice was not farnesylated, we incubated Lmna HG/+ and Lmna csmHG/+ fibroblasts with 8-anilinogeraniol (AG), a farnesol analog (11, 12, (18) (19) (20) (21) . AG is incorporated into anilinogeranyl diphosphate in cells and then used as a substrate by protein farnesyltransferase (FTase). Western blotting with an AG-specific antibody was used to detect farnesylated proteins. Farnesylated proteins were detected between lamin A and lamin C in all cell lines, corresponding to lamins B1 and B2, which have migration patterns similar to progerin (Fig. 2) . When we examined proteins immunoprecipitated with a lamin A/C antibody, we observed farnesylated progerin in Lmna HG/+ cells but not in Lmna csmHG/+ or Lmna +/+ cells (Fig. 2) . The incorporation of AG into proteins was eliminated with an FTI (Fig. 2) .
The (Fig. 3) . In contrast, Lmna nHG/+ and Lmna nHG/nHG mice exhibited abnormal body weight curves, reduced survival and reduced adipose tissue stores (P , 0.0001) (Fig. 3A-D) . Also, Lmna nHG/+ and Lmna nHG/nHG mice developed osteolytic lesions and spontaneous rib fractures, whereas Lmna csmHG/+ and Lmna csmHG/csmHG mice did not ( Fig. 4A-D) . Finally, bone density was reduced in Lmna nHG/nHG mice but was normal in Lmna csmHG/csmHG mice (Fig. 4E ). These differences could not be explained by an unintentional mutation in the knock-in alleles; progerin transcripts from Lmna nHG/+ and Lmna csmHG/+ mice were sequenced and were identical, except for the targeted mutation (data not shown).
Certain missense mutations in LMNA are known to cause cardiomyopathy with conduction system disease (22) , but cardiomyopathy is not a general feature of HGPS. At 12 months of age, Lmna csmHG/csmHG mice exhibited slightly reduced left ventricular posterior wall thickness (Fig. 5A ) and ejection fraction (Fig. 5B) , as judged by echocardiography, but these abnormalities were mild. No instances of sudden death were observed in our Lmna csmHG/csmHG colony, even in mice .1-year-old, and no histopathological abnormalities could be identified (data not shown).
Misshapen nuclei are common in human HGPS fibroblasts (1, 2, 23 Lmna nHG/nHG mice was located at the nuclear rim, indistinguishable from the location of lamin A in Lmna +/+ mice (Fig. 7) .
The milder disease phenotypes in Lmna nHG/+ mice, compared with Lmna HG/+ mice, were accompanied by lower steady-state levels of progerin, both in embryonic fibroblasts and tissues of adult mice (12) . Given the complete absence of disease phenotypes in Lmna csmHG/+ mice, we initially suspected that progerin levels in Lmna csmHG/+ mice would be much lower than in Lmna nHG/+ mice (12). That was not the case. The levels of progerin in Lmna csmHG/+ and Lmna nHG/+ fibroblasts (n ¼ 4 cell lines/genotype) were similar, as were progerin levels in tissues of Lmna csmHG/+ and Lmna nHG/+ mice (except in the liver, where progerin levels in Lmna csmHG/+ mice were slightly higher than in Lmna nHG/+ mice). Progerin levels in Lmna csmHG/+ and Lmna nHG/+ fibroblasts and tissues were lower than in Lmna HG/+ fibroblasts and tissues (P , 0.0001) (Fig. 8) . and Lmna HG/+ mice (9, 28) . The encouraging results led to a clinical trial of FTI treatment in humans with HGPS (29, 30) . However, some of the enthusiasm about FTI therapy was dampened by the discovery of severe progeria-like disease phenotypes in mice expressing non-farnesylated progerin (Lmna nHG/+ ). At face value, the findings in Lmna nHG/+ mice implied that the real culprit in HGPS might be progerin's 50-amino acid deletion (rather than its lipid anchor) and that any benefits of 'anti-protein prenylation therapy' would be limited. However, those conclusions depend on a key premise-that the effects of SSIM progerin are similar to those of the non-prenylated CSIM progerin that accumulates when Lmna HG/+ mice are treated with an FTI. In the current study, we further evaluated the effects of non-prenylated progerin. We did so by creating a new knock-in allele for non-farnesylated progerin, Lmna csmHG , encoding a progerin in which the isoleucine of the CaaX motif is deleted. Like SSIM progerin (12) , the CSM progerin from the Lmna csmHG allele could not be prenylated. Remarkably, Lmna csmHG/+ and Lmna csmHG/csmHG mice were free of progeria-like disease phenotypes. In contrast, Lmna nHG/+ and Lmna nHG/nHG mice developed severe disease (slow growth, osteolytic lesions in the bones, reduced bone density, reduced adipose tissue stores and reduced survival). Nuclear shape abnormalities were also milder in Lmna csmHG/+ and Lmna csmHG/csmHG fibroblasts. The current studies demonstrate that the toxicity of non-farnesylated progerin depends on the mutation used to abolish protein farnesylation. Also, these studies cast doubt on the notion that progerin's 50-amino acid internal deletion is central to disease pathogenesis.
DISCUSSION
We considered the possibility that progerin produced from the Lmna nHG or Lmna csmHG allele contained some unintended mutation that explained the different phenotypes, but this was not the case. Except for the targeted mutation, the sequences of progerin transcripts from Lmna nHG/+ and Lmna csmHG/+ mice were identical. Also, one could not ascribe the different phenotypes to different steady-state levels of progerin. The progerin levels in Lmna nHG/+ and Lmna csmHG/+ fibroblasts were similar, as were progerin levels in tissues of Lmna nHG/+ and Lmna csmHG/+ mice (the progerin levels in liver actually appeared to be somewhat higher in Lmna csmHG/+ mice). In the description of the Lmna nHG/+ mice, Yang et al. (12) raised the formal possibility that the cysteine-to-serine substitution could be responsible for the toxicity of SSIM progerin. Given the subtle nature of the amino acid substitution, that possibility initially seemed unlikely. But the absence of progeria-like disease phenotypes in Lmna csmHG/+ and Lmna csmHG/csmHG mice means that this possibility cannot be dismissed. Why the CSM progerin did not yield progeria-like disease phenotypes is unknown, but it is conceivable that the free cysteine in the carboxyl-terminus of CSM progerin somehow protects from disease. If so, the CSIM progerin that accumulates in the setting of FTI treatment might be nontoxic. At this point, we cannot state with confidence which of the two 'non-farnesylated knock-in alleles' yields the most faithful and relevant model for HGPS treatment, but we tend to think that it is the Lmna csmHG allele. In large part, we say this because the health and vitality of the Lmna csmHG/csmHG mice were so striking, but one cannot exclude the possibility that progerin's 50-amino acid deletion is intrinsically toxic and that the isoleucine deletion in the Lmna csmHG allele neutralizes the toxicity. Also, the absence of progeria-like phenotypes in mice expressing CSM progerin is consistent with observations on farnesylated and nonfarnesylated versions of full-length prelamin A. A farnesylated full-length prelamin A (in the setting of ZMPSTE24 deficiency) causes a severe progeroid syndrome in both humans and mice (6,24,31 -38) . In contrast, mice expressing non-farnesylated full-length prelamin A had no progeria-like disease phenotypes (although they eventually developed cardiomyopathy and sudden death) (21) . In the current study, we found mild left ventricular dysfunction in Lmna csmHG/csmHG mice, but we never observed sudden death. As noted earlier, the ideal experiment would be to create 'nonfarnesylated progerin mice' without introducing any mutation into progerin's CaaX motif. In theory, one could achieve this goal by eliminating the expression of the protein prenyltransferases, but this approach would be fraught with difficultiessimply because deficiencies of those enzymes elicit severe disease. For example, a deficiency of FTase in skin keratinocytes causes severe alopecia (39) , and a deficiency of FTase in hepatocytes causes severe hepatocellular disease (Shao H. Yang, unpublished data). Moreover, it is possible that eliminating protein farnesylation would not be sufficient to eliminate the prenylation of progerin, as recent studies have suggested that progerin could be geranylgeranylated when FTase activity is inhibited with an FTI (40) . Eliminating both protein farnesylation and protein geranylgeranylation in the liver is associated with more severe pathology than eliminating protein farnesylation alone (Shao H. Yang, unpublished data).
It is interesting that the progerin in the liver of Lmna csmHG/csmHG and Lmna nHG/nHG mice was positioned quite normally at the nuclear rim. We did not find this particularly surprising. Although protein prenylation is often assumed to be crucial for the targeting of lamin A to the nuclear rim (8, 23) , recent observations indicate that this is not the case (21, 39, 41) . For example, in mice that express mature lamin A directly (completely bypassing prelamin A synthesis and prelamin A farnesylation), the mature lamin A in mouse tissues reaches the nuclear rim quite normally (41) . Also, nonfarnesylated prelamin A is normally positioned at the nuclear rim in the tissues of knock-in mice expressing only nonfarnesylated prelamin A (21). Finally, the prelamin A that accumulates in FTase-deficient skin keratinocytes is targeted to the nuclear rim (39) .
In summary, mice harboring the Lmna csmHG allele are free of progeria. Even the homozygous mice, which produce exclusively progerin and no lamin A or lamin C, lack all of the hallmarks of progeria. The absence of progeria in Lmna csmHG/+ and Lmna csmHG/csmHG mice sounds an encouraging note to those interested in treating progeria with drugs that inhibit protein prenylation.
MATERIALS AND METHODS

Generation of Lmna csmHG mice
To generate a mutant Lmna allele yielding non-farnesylated progerin (Lmna csmHG ), we used a gene-targeting vector identical to one used to create a mutant allele yielding farnesylated progerin (Lmna HG ) (8) , except that it contained a 3 bp deletion in exon 12 (within the 5 ′ arm of the vector). The short deletion eliminates the isoleucine of the CaaX motif. The mutation was introduced into the 5 ′ -arm of the vector with the QuikChange mutagenesis kit (Stratagene, La Jolla, CA, USA) with primer 5
′ -CAGAGC TCCCAGAACTGCAGCATGTAATCT-3 ′ and a complementary reverse primer. The integrity of the gene-targeting vector was verified by restriction endonuclease digestion and DNA sequencing.
ES cell clones (strain 129/OlaHsd) carrying the Lmna csmHG allele were identified by Southern blotting with EcoRI-cleaved genomic DNA and a 348 bp 5 ′ -flanking probe (8) . The probe detects a 10.4 kb band in the wild-type Lmna allele and a 9.3 kb band in the Lmna csmHG allele. Targeted ES cells were used to generate male chimeric mice, which were bred with C57BL/6 females to generate heterozygous knock-in mice (Lmna csmHG/+ ). Lmna csmHG/+ mice were intercrossed to generate homozygous mice (Lmna csmHG/csmHG ). Mice were genotyped by PCR with genomic DNA and oligonucleotide primers 5 ′ -TGAGTACAACCTGCGCTCAC-3 ′ and 5 ′ -CAGACAGG AGGTGGCATGT-3 ′ . The wild-type allele yields a 582 bp PCR product, while the mutant allele yields a 183 bp product.
The phenotypes of Lmna csmHG/+ and Lmna csmHG/csmHG mice were compared, side-by-side, with Lmna nHG/+ and Lmna nHG/nHG mice (12) . Lmna csmHG/+ and Lmna nHG/+ mice were bred from chimeras; thus, they were genetically identical except for distinct CaaX motif mutations (with one C57BL/6 chromosome and one 129/OlaHsd chromosome). Homozygous knock-in mice had a mixed genetic background. All mice were weaned at 21 days of age, housed in a virus-free barrier facility with a 12 h light-dark cycle and fed a chow diet containing 4.5% fat. 440
Cell culture
Primary fibroblasts were isolated from E13.5 embryos and cultured in standard fibroblast culture medium (8, 10, 34, 42) . In some experiments, protein farnesylation was blocked by incubating cells for 48 h with a selective FTI (ABT-100, 5 mM).
Metabolic labeling studies to assess protein farnesylation
Fibroblasts were plated in six-well dishes and grown to 75% confluency. 8-Anilinogeraniol (AG, 30 mM in DMSO) (18, 19) was added to the cell culture medium and incubated for 48 h in the presence or absence of ABT-100 (5 mM). The incorporation of AG into proteins such as progerin was detected by western blotting with an AG-specific monoclonal antibody (1:5000) (18) . In some experiments, A-type lamins were immunoprecipitated with a goat anti-lamin A/C antibody (15 ml) (Santa Cruz Biotechnology). Protein samples were size-fractionated on 4 -12% polyacrylamide Bis -Tris gels (Invitrogen, Carlsbad, CA, USA) and then transferred to nitrocellulose for western blotting. The antibody dilutions were 1:400 for goat anti-lamin A/C IgG (sc-6215, Santa Cruz Biotechnology), 1:5000 for anti-AG mouse IgG and 1:1000 for anti-actin goat IgG (sc-1616, Santa Cruz Biotechnology). After washing, the membranes were incubated with 1:5000 IRDye 800 anti-goat IgG or 1:5000 IRDye 680 anti-mouse IgG (Li-Cor, Lincoln, NE, USA). Signals were detected with an Odyssey infrared imaging scanner.
Protein extraction and western blots
Protein extracts were prepared from early-passage fibroblasts with a urea-containing solubilization buffer (43) . To make protein extracts from mouse tissues, tissues ( 150 mg) were snap-frozen in liquid nitrogen and then ground into a powder with a mortar and pestle. The powder was resuspended in 0.5 ml of urea solubilization buffer (43) and then homogenized with a glass tissue grinder for 2 min. The samples were then sonicated and cleared by centrifugation (14 000g for 10 min). Extracts were size-fractionated on 4 -12% polyacrylamide Bis -Tris gels (Invitrogen), and the separated proteins transferred to nitrocellulose for western blotting. Antibody dilutions were 1:400 for goat anti-lamin A/C IgG (sc-6215, Santa Cruz Biotechnology), 1:1000 for goat antiactin IgG (sc-1616, Santa Cruz Biotechnology) and 1:5000 for IRDye 800 anti-goat IgG (Rockland Immunochemicals, Gilbertsville, PA, USA). The IR-coupled antibodies were detected with an Odyssey infrared imaging scanner.
Immunofluorescence microscopy
Primary fibroblasts were plated on coverslips in 24-well plates, and grown to 75% confluency. Fibroblasts were fixed in 3% paraformaldehyde, permeabilized with 0.2% Triton X-100 and blocked with PBS containing 10% fetal bovine serum and 0.2% bovine serum albumin (8, 23, 24) . Cells were incubated for 1 h with antibodies against lamin A (1:200, sc-20680, Santa Cruz Biotechnology). After washing, cells were incubated with 1:800 Cy3-conjugated anti-rabbit antibody (Jackson ImmunoResearch Laboratories, West Grove, PA, USA) and DAPI (to visualize DNA). Liver sections of adult mice were also stained with the antibody against lamin A. Images were obtained on an Axiovert 200 MOT microscope (Carl Zeiss, Thornwood, NY, USA) with a 63×/ 1.25 oil immersion objective and processed with AxoVision 4.2 software (Zeiss). Nuclear shape (2000 cells per genotype) was assessed in a blinded fashion (8, 12, 23, 44 ) (see also Supplementary Material, Fig. S1 ).
Mouse phenotypes
Body weights were assessed weekly for 48 weeks; numbers of surviving mice were also recorded weekly. Lmna +/+ , Lmna csmHG/+ and Lmna csmHG/csmHG mice were euthanized at 12 months of age. Lmna nHG/+ and Lmna nHG/nHG developed progressive inanition and were euthanized after their body weight dropped by 2 g within a week (as specified by UCLA veterinary staff). To assess the amount of adipose tissue in mice, the major fat pads (reproductive, inguinal and mesenteric) were removed and weighed. To assess bone disease, the thoracic cavity of Lmna and Lmna +/+ mice was photographed after removing the heart and lung, and the numbers of rib fractures were counted (12, 24, 28, 45) . To assess bone density, Lmna csmHG/csmHG , Lmna nHG/nHG and Lmna +/+ mice were examined by X-ray micro-computed tomography (mCT) with the SkyScan 1172 system scanner (SKYSCAN, Belgium). Bone density of ribs was determined by mCT scanning in a cylindrical sample holder tube with a voltage of 55 kVp and current of 143 mA. Three-dimensional images were reconstructed in 2048 × 2048 pixel matrices, and a cortical volume of interest was defined for each measurement. The mineralized tissue was segmented with a threshold of 71 for all samples. A hydroxyapatite phantom of known density was used for calibration. To measure the left ventricular posterior wall thickness and ejection fraction, Lmna +/+ and Lmna csmHG/csmHG mice were examined by echocardiography (21) .
Statistical analyses
Body weight curves were compared with repeated-measures ANOVA and the log-rank test. The bone density, number of rib fractures and fat pad weights were compared with a two-tailed Student's t-test. Differences in the percentages of misshapen nuclei were assessed with a x 2 -test. The significance of survival differences was assessed with a Kaplan-Meier test. , and Lmna csmHG/+ mice (n ¼ 4/genotype). In both tissues and the fibroblasts, the progerin:actin ratio was lower in Lmna nHG/+ and Lmna csmHG/+ mice than Lmna HG/+ mice (P , 0.0001); the progerin:actin ratio in the liver was higher in Lmna csmHG/+ mice than in Lmna nHG/+ mice (P ¼ 0.01). Each sample was analyzed on two western blots; the variation in the progerin:actin ratio averaged 3.6%. Progerin:actin ratios in Lmna nHG/+ and Lmna csmHG/+ mice samples were expressed relative to those in Lmna HG/+ samples (which were set at one).
